Emergent Biosolutions
EBS
EBS
272 hedge funds and large institutions have $2.21B invested in Emergent Biosolutions in 2018 Q1 according to their latest regulatory filings, with 55 funds opening new positions, 98 increasing their positions, 79 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
272
Holders Change
+34
Holders Change %
+14.29%
% of All Funds
6.24%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
55
Increased
98
Reduced
79
Closed
17
Calls
$1.36M
Puts
–
Net Calls
+$1.36M
Net Calls Change
+$1.97M
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$29.5M |
| 2 |
Prudential Financial
Newark,
New Jersey
|
+$17.9M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$16.8M |
| 4 |
Renaissance Technologies
New York
|
+$14.9M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$13.4M |
Top Sellers
| 1 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$34.7M |
| 2 |
LSV Asset Management
Chicago,
Illinois
|
-$28M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$23.1M |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$13.6M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$9.66M |
